Ogwulu CBO, Goranitis I, Devall AJ, et al. - Researchers performed an economic evaluation alongside a large multi-center randomized placebo-controlled trial in order to determine the cost-effectiveness of progesterone vs placebo in preventing pregnancy loss in women with early pregnancy vaginal bleeding. From 48 UK NHS early pregnancy units, they identified 4,153 women (aged 16–39 years) with bleeding in early pregnancy and ultrasound evidence of an intrauterine sac for assessment in this work. Outcomes revealed a small positive impact and a small additional cost in correlation to progesterone use. The average cost per participant was £7,655 compared with £7572 for the placebo. The difference in costs (£76, 95% CI −£559 to £711) was principally related to the cost of progesterone (£204). The results of the cost-effectiveness analysis reported here suggest the possibility of progesterone to be a cost-effective option for all women at risk, however, this was especially noted for women with one or more previous miscarriages who present with bleeding in early pregnancy. This analysis lends support to the belief of providing progesterone to such women on cost-effectiveness grounds.